Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

the latest tech news, global tech news daily, tech news today, startups, usa tech, asia tech, china tech, eu tech, global tech, in-depth electronics reviews, 24h tech news, 24h tech news, top mobile apps, tech news daily, gaming hardware, big tech news, useful technology tips, expert interviews, reporting on the business of technology, venture capital funding, programing language

Catalent, Inc. CTLT is scheduled to report second-quarter fiscal 2022 results on Feb 1, before market open.

second-quarter fiscal 2022 results, Catalent, Inc. price-eps-surprise, Catalent, Inc. Quote, Earnings ESP, Earnings ESP Filter, Zacks Earnings Calendar, Click to get this free report, Zacks Investment Research
– Zacks

In the last-reported quarter, the company’s earnings of 71 cents per share surpassed the Zacks Consensus Estimate by 7.6%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 9.88%, on average.

the latest tech news, global tech news daily, tech news today, startups, usa tech, asia tech, china tech, eu tech, global tech, in-depth electronics reviews, 24h tech news, 24h tech news, top mobile apps, tech news daily, gaming hardware, big tech news, useful technology tips, expert interviews, reporting on the business of technology, venture capital funding, programing language

Let’s see how things have shaped up prior to this announcement.

Factors to Note

Biologics Business

Per Catalent’s November 2021 earnings update, the Biologics segment has been witnessing strength over the past few months on the back of continued high demand for COVID-19-related products. Since the volume of work related to COVID-19 vaccines and treatments continues to remain high, the segment is expected to have maintained its strength in the second quarter of fiscal 2022 as well, thereby contributing to revenues.

Global Tech News Daily

The company also confirmed during its fiscal first-quarter earnings call that its campus in Bloomington, IN had been undergoing upgrades. These upgrades have served as a key growth driver for Catalent, having enabled the company to quickly scale up high-speed filling lines on behalf of its COVID-19 vaccine customers. As the demand for pandemic-related products continues to remain high, this scaling up of production is likely to have driven Catalent’s fiscal second-quarter top line.

Catalent, Inc. Price and EPS Surprise

second-quarter fiscal 2022 results, Catalent, Inc. price-eps-surprise, Catalent, Inc. Quote, Earnings ESP, Earnings ESP Filter, Zacks Earnings Calendar, Click to get this free report, Zacks Investment Research

Global Tech News Daily

Catalent, Inc. price-eps-surprise | Catalent, Inc. Quote

Catalent, in October 2021, announced an expansion project to add three more commercial-scale viral vector manufacturing suites, and associated support facilities and services at its gene therapy campus in Harmans, MD to meet the growing customer demand. The company also confirmed the completion of the addition of a new high-speed syringe filling line (initially announced in 2019) during its previous earnings call, which is an additional source of growth for the Biologics segment. Apart from this, Catalent continues to benefit from its facility in Anagni, Italy. These developments are likely to have driven the segmental revenues of the to-be-reported quarter.

A notable development in the to-be-reported quarter is the finalization of the technology transfer for NurOwn manufacturing at Catalent’s facility in December 2021. NurOwn is BrainStorm Cell Therapeutics Inc.’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis, progressive multiple sclerosis and other neurodegenerative diseases.

The Zacks Consensus Estimate for second-quarter Biologics revenues is pegged at $585 million, suggesting a surge of 44.8% from the year-ago quarter’s reported figure.

Other Factors

Catalent’s Clinical Supply Services arm is likely to have continued its strength in the to-be-reported quarter on the back of strong demand for the company’s manufacturing and packaging, and storage and distribution offerings.

In October 2021, the company opened a new facility in San Diego, CA in response to higher demand from pharmaceutical and biopharmaceutical customers for integrated development, clinical packaging and distribution solutions on the U.S. West Coast. The same month, Catalent opened its new clinical supply facility in the Shiga prefecture of Japan to meet the growing demand for end-to-end services, including primary packaging and white glove services. These developments are likely to have considerably driven segmental revenues in the to-be-reported quarter.

The Zacks Consensus Estimate for fiscal second-quarter Clinical Supply Services revenues stands at $100 million, indicating 6.4% growth from the year-ago quarter’s reported figure.

On the flip side, Catalent’s fiscal 2022 second-quarter top line is likely to have been hurt by lower revenues from its Softgel and Oral Technologies segment, which has been witnessing pandemic-induced headwinds over the past few months. Although the impacts are gradually lessening, revenues are likely to be negatively impacted to some extent by the continued pandemic-led challenging business environment.

However, increased year-over-year demand for both prescription and consumer health products is likely to have pushed up quarterly revenues, thereby partly offsetting the pandemic-led headwinds. Catalent’s closing of the Bettera Holdings buyout in October also raises our optimism.

The Estimate Picture

For second-quarter fiscal 2022, the Zacks Consensus Estimate for total revenues of $1.16 billion implies an improvement of 27.2% from the prior-year quarter’s reported figure.

The consensus estimate for earnings is pegged at 84 cents per share, implying an uptick of 33.3% from the prior-year quarter’s reported number.

What Our Model Suggests

Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here as you can see:

Earnings ESP: Catalent has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #2.

Stocks Worth a Look

Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.

AMN Healthcare Services, Inc. AMN has an Earnings ESP of +10.29% and a Zacks Rank of 1. AMN has an estimated long-term growth rate of 16.2%.

AMN Healthcare’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.51%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Hologic, Inc. HOLX has an Earnings ESP of +1.56% and a Zacks Rank of 2, at present. HOLX has an estimated long-term growth rate of 7.4%.

Hologic’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 29.15%.

Henry Schein, Inc. HSIC has an Earnings ESP of +2.62% and is a Zacks #2 Ranked stock. HSIC has an estimated long-term growth rate of 11.8%.

Henry Schein’s earnings surpassed estimates in the trailing four quarters, the average surprise being 21.86%.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.


Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Hologic, Inc. (HOLX): Free Stock Analysis Report

 

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

 

AMN Healthcare Services Inc (AMN): Free Stock Analysis Report

 

Catalent, Inc. (CTLT): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research

News Related

OTHER NEWS

Rel Capital resolution: Lenders hire KPMG India, L&L Partners

Lenders to Reliance Capital have appointed KPMG India as their process advisor andetL&L Partners the legal counsel to help negotiate the challenges in the resolution of Anil Ambani-promoted Reliance Capital, ... Read more »

Soaring refining margin bodes well for oil firms

The industrial complex in the southern port city of Ulsan where production bases of Korea’s major petrochemical companies are located (Yonhap)South Korean oil refiners’ key profitability measure has been rising ... Read more »

Buckle (BKE) Gains As Market Dips: What You Should Know

Buckle (BKE) closed at $37.24 in the latest trading session, marking a +1.36% move from the prior day. This change outpaced the S&P 500’s 0.37% loss on the day. – ... Read more »

AutoNation (AN) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AutoNation (AN) closed at $103.57, marking a -0.46% move from the previous day. This change lagged the S&P 500’s 0.37% loss on the day. – ... Read more »

FuboTV Inc. (FUBO) Stock Moves -0.3%: What You Should Know

fuboTV Inc. (FUBO) closed at $10.07 in the latest trading session, marking a -0.3% move from the prior day. This change was narrower than the S&P 500’s 0.37% loss on ... Read more »

Fiverr International (FVRR) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Fiverr International (FVRR) closed at $81.01, marking a -0.52% move from the previous day. This change lagged the S&P 500’s daily loss of 0.37%. – ... Read more »

Sterling Construction (STRL) Gains As Market Dips: What You Should Know

Sterling Construction (STRL) closed at $27.51 in the latest trading session, marking a +1.63% move from the prior day. The stock outpaced the S&P 500’s daily loss of 0.37%. – ... Read more »

Boise Cascade (BCC) Gains As Market Dips: What You Should Know

Boise Cascade (BCC) closed at $77.20 in the latest trading session, marking a +0.69% move from the prior day. The stock outpaced the S&P 500’s daily loss of 0.37%. – ... Read more »

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $62.36, marking a +0.76% move from the previous day. This move outpaced the S&P 500’s daily loss of 0.37%. ... Read more »

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

Bausch Health (BHC) closed the most recent trading day at $24.39, moving -0.53% from the previous trading session. This move lagged the S&P 500’s daily loss of 0.37%. – Zacks ... Read more »

ETF Strategies to Consider for February as Fed's Rate Hike Nears

Wall Street has been mostly kind to investors so far in February after a tough January. Market participants are upbeat about improving U.S. economic conditions as reflected by encouraging fourth-quarter ... Read more »

Bank of Nova Scotia (BNS) Gains As Market Dips: What You Should Know

Bank of Nova Scotia (BNS) closed at $73.75 in the latest trading session, marking a +0.78% move from the prior day. This move outpaced the S&P 500’s daily loss of ... Read more »

Fox (FOXA) to Report Q2 Earnings: What's in the Offing?

Fox FOXA is set to report second-quarter fiscal 2022 results on Feb 9.For the quarter, the company’s current Zacks Consensus Estimate for earnings is pegged at breakeven against a loss ... Read more »

Generac Holdings (GNRC) Gains As Market Dips: What You Should Know

In the latest trading session, Generac Holdings (GNRC) closed at $279.97, marking a +0.01% move from the previous day. This move outpaced the S&P 500’s daily loss of 0.37%. – ... Read more »

Spirit And Frontier Announce $6.6 Billion Merger

Spirit Airlines Incorporated (NYSE:SAVE) and Frontier Group Holdings Inc (NASDAQ:ULCC) have announced a $6.6 billion merger to create one of the largest low-cost airlines in the U.S. The new airline ... Read more »

First Trust Energy AlphaDEX Fund (FXN) Hits a 52-Week High

The First Trust Energy AlphaDEX Fund FXN is probably a suitable pick for investors looking for momentum. FXN hit a 52-week high and is up 59.6% from its 52-week low ... Read more »

Meta Threatens To Close Facebook And Instagram In Europe Over Data Scramble

In a document filed with the U.S. Securities and Exchange Commission (SEC), Meta Platforms Inc (NASDAQ:FB) has warned it could be forced to close Facebook and Instagram in Europe if ... Read more »

Stock futures inch higher after S&P, Nasdaq fall to start the week

U.S. stock index futures crept higher during overnight trading Monday, after the major averages moved between gains and losses during regular trading as the market awaits key inflation data later ... Read more »

How a To-Don't List Can Help You Achieve Your Goals

To-do lists are helpful tools for many people, but they can quickly take over our lives, making daily living feel like just another item to cross off of a never-ending ... Read more »

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3

Immunovant, Inc. IMVT reported a net loss of 36 cents per share in the third quarter of fiscal 2022 (ended Dec 31, 2021), wider than the Zacks Consensus Estimate of ... Read more »

Buckle's (BKE) Sales Run Continues in January, Comps Gain 4.2%

The Buckle, Inc. BKE looks well poised on the back of its robust strategic efforts, including strength in e-commerce business and an impressive sales trend. BKE has been putting up ... Read more »

6 Best-Leveraged ETF Areas of Last Week

Wall Street put up a moderate show last week with the S&P 500 (up 1.6%), the Dow Jones (up 1.1%), the Nasdaq Composite (up 2.4%) and the Russell 2000 (up ... Read more »

Interpublic (IPG) to Report Q4 Earnings: What's in the Cards?

The Interpublic Group of Companies, Inc. IPG is scheduled to report fourth-quarter 2021 results on Feb 10, before the opening bell. – Zacks Let’s check out how things have shaped ... Read more »

Mednax (MD) Buys Night Lite Pediatrics to Boost Portfolio

Mednax, Inc. MD and its affiliated practices Pediatrix Medical Group recently acquired Night Lite Pediatrics, LLC in Orlando, FL. Night Lite is a private 13-clinic pediatric urgent care practice. The ... Read more »

Best Growth Stocks to Buy for February 7th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 7th: – Zacks Apple AAPL: This company whose business primarily runs around its ... Read more »

Gol Linhas (GOL) Stock up 16.2% in a Month: More Upside Left?

Shares of Gol Linhas GOL have displayed an uptrend on the bourses over the past month, gaining 16.2% against its industry’s 3.1% decline. – Zacks Image Source: Zacks Investment Research ... Read more »

Top Research Reports for Bank of America, Coca-Cola & salesforce

Monday, February 7, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Bank ... Read more »

Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

Sanofi SNY announced that the FDA has approved its monoclonal antibody, Enjaymo (sutimlimab-jome), to decrease the need for red blood cell transfusion due to hemolysis in adult patients with cold ... Read more »

The Zacks Analyst Blog Highlights: Alphabet, T-Mobile US, Advanced Micro Devices, Mondelez International and Chubb

For Immediate Release Chicago, IL – February 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ... Read more »

IRS to stop using facial recognition for identity verification

Signage outside the Internal Revenue Service (IRS) headquarters in Washington, D.C.Bloomberg | Bloomberg | Getty Images The IRS on Monday announced it will stop using a controversial third-party service for ... Read more »

Why Mid-America Apartment Communities (MAA) is a Great Dividend Stock Right Now

Whether it’s through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you’re an income investor, your primary focus is ... Read more »

On Core Values, Self-Honesty and Having Fun with Jairek Robbins, the New President of SUCCESS

“You gotta answer your DMs, man,” says Jairek Robbins, half laughing, in his latest Brilliant Thoughts interview with Tristan Ahumada. Robbins, who is an acclaimed business coach, best-selling author and ... Read more »

Surging Earnings Estimates Signal Upside for Xilinx (XLNX) Stock

Investors might want to bet on Xilinx (XLNX), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and ... Read more »

BCB Bancorp (BCBP) is a Top Dividend Stock Right Now: Should You Buy?

Whether it’s through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you’re an income investor, your primary focus is ... Read more »

The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer

For Immediate Release Chicago, IL – February 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ... Read more »

BankUnited (BKU) Stock up 3.4% on New Share Repurchase Plan

BankUnited, Inc. BKU has announced a new share repurchase plan. The company’s board of directors has approved the repurchase of up to $150 million in shares of BKU’s outstanding stock. ... Read more »

TEGNA Inc. (TGNA) Soars 7.4%: Is Further Upside Left in the Stock?

TEGNA Inc. TGNA shares rallied 7.4% in the last trading session to close at $21.34. This move can be attributable to notable volume with a higher number of shares being ... Read more »

Can BCB Bancorp (BCBP) Run Higher on Rising Earnings Estimates?

BCB Bancorp (BCBP) could be a solid choice for investors given the company’s remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue ... Read more »

Earnings Estimates Moving Higher for Marathon Oil (MRO): Time to Buy?

Marathon Oil (MRO) could be a solid choice for investors given the company’s remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue ... Read more »

Transport ETFs to Buy on Solid Q4 Earnings

The fourth-quarter earnings picture for the transportation sector has been robust. This is especially true as earnings of 95.2% of the market capitalization of the sector that has reported so ... Read more »